Conditions: Prostate Cancer
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 23
Healthy volunteers: no

Brief summary:
The purpose of this study is to evaluate the safety and effectiveness of bevacizumab plus erlotinib following radical prostatectomy.

Detailed description:
This study explores the anti-tumor activity of adjuvant bevacizumab plus erlotinib in a select group of prostate cancer patients deemed at high risk for early relapse following radical prostatectomy.

Arms:
arm 1: Participants received Erlotinib every day for 24 weeks and Bevacizumab every 3 weeks for a total of 8 doses

Interventions: intervention 1: Erlotinib + Bevacizumab
Intervention descriptions: intervention 1: Erlotinib every day for 24 weeks and Bevacizumab every 3 weeks for a total of 8 doses

Protocol document: